THERAPEUTICS

Trained Therapeutix Discovery Inc.’s Exclusively Licensed Technology Shown to Suppress Cancer Growth

2 November, 2020
Trained Therapeutix Discovery, Inc. (“TTxD”), an immunotherapy biotech company founded by Jean Boulle Therapeutics, notes the results of a preclinical Study (“the Study”) published in Cell showing how nanobiologic immunotherapy promotes trained immunity and elicits a durable anti-tumor response either as a monotherapy or in combination with other checkpoint inhibitor drugs. [...]

Landmark trial shows trained immunity reduces respiratory infections in the elderly by 80% 

September 1 2020
Trained Therapeutix Discovery, Inc. (“TTxD”), an immunotherapy biotech company founded by Jean Boulle Therapeutics, notes the results of a clinical trial1 (“the Trial”) published in Cell showing that trained immunity through the use of BCG vaccination can reduce respiratory tract infections by 80% amongst elderly people including, potentially, COVID-19. [...]

Jean Boulle Medtech’s New Therapeutics Technology Platform Targets Trained Immunity for COVID-19 Patients and Resultant Acute Respiratory Distress Syndrome

April 27 2020
Trained Therapeutix Discovery, Inc. (“TTxD”), an immunotherapy biotech company founded by Jean Boulle Medtech, is testing a unique strategy for treating Acute Respiratory Distress Syndrome1 (“ARDS”), which could prove to be highly effective in saving the lives of COVID–19 patients [...]

HEAD OFFICE
25B Boulevard Royal
L2449 Luxembourg
Grand Duchy Luxembourg

CALL US
Tel: +352 222 512
Fax: +352 222 413

Copyright © 2019 Jean Boulle Group. All rights reserved.